NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added
Policy / Regulatory

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

The National Medical Products Administration (NMPA) has released the 110th batch of the Catalog of Reference Listed Drugs (RLD) for Chemical Generic Drugs, adding 28 new drug specifications and providing…

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
CompanyDrug

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo's ADC Wins Conditional Approval for HER2-Expressing Solid Tumors
CompanyDrug

Enhertu Approved in China as First Tumor-Agnostic HER2-Targeted Therapy – Daiichi Sankyo’s ADC Wins Conditional Approval for HER2-Expressing Solid Tumors

European Commission Approves Novartis' Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe
CompanyDrug

European Commission Approves Novartis’ Cosentyx for Polymyalgia Rheumatica – First and Only IL-17A Inhibitor for Adult PMR in Europe

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH
CompanyDrug

LongBio Pharma Reports Positive Top-Line Phase II Data for LP-005 – Bifunctional C5/C3b Antibody Achieves 100% Hemolysis Control in PNH

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GlaxoSmithKline Plc (GSK; NYSE: GSK) announced the first global data for risvutatug rezetecan (Ris‑Rez, HS‑20093), its investigational B7‑H3‑targeted antibody‑drug conjugate (ADC), in patients with relapsed extensive‑stage small cell lung cancer (ES‑SCLC). Results from the Phase Ib dose‑optimization portion of the…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio
CompanyDeals

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline
CompanyDeals

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed
Company

Roche Reports 9M 2026 Sales of CHF 46.493 Billion, Up 6% at CER – Ocrevus Leads as Pharmaceuticals Division Drives Growth and Full-Year Guidance Is Confirmed

European Commission Approves Merck's KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU
CompanyDrug

European Commission Approves Merck’s KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing
CompanyDeals

Siemens Healthineers and NVIDIA Partner to Develop Next-Generation Adaptive Radiotherapy Technology – Combining Agentic and Robotic Intelligence With Accelerated Computing

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China's First Senotherapeutics Biotech Backed by Top-Tier Investors
CompanyDeals

Reju Therapeutics Completes Oversubscribed Series A Financing of Hundreds of Millions of RMB – China’s First Senotherapeutics Biotech Backed by Top-Tier Investors

Reju Therapeutics, the first biotech company in China targeting aging biology, announced the completion of an oversubscribed Series A financing round of hundreds of millions of RMB. The round was…

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio
CompanyDeals

OrbusNeich Completes Acquisition of Italian Distributor MC Health – 100% Equity Deal Shifts Italy Operations to Direct Sales Model for Coronary Portfolio

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally
CompanyDeals

HutchMed Completes USD 1.295 Billion Licensing Transaction with GSK for HMPL‑A830 – First‑in‑Class KRAS‑Inhibitor ATTC Targets EGFR‑Expressing Tumors Globally

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio
CompanyDeals

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global
CompanyDeals

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Pilot Plan for Promoting the Research and Application of New Approach Methodologies (the "Pioneer Plan"),…

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition
Policy / Regulatory

MOFCOM and MOST Open Consultation on Revised Technology Export Catalogue – 40 Technologies Across AI, Biopharmaceuticals and Photovoltaics Proposed for Addition

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs

More News

Abbott to Separate Nutrition Business Into Independent Public Company – USD 8.5 Billion Global Leader in Healthy Nutrition
Company

Abbott to Separate Nutrition Business Into Independent Public Company – USD 8.5 Billion Global Leader in Healthy Nutrition

Biostar's Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer
CompanyDrug

Biostar’s Oral Utidelone Capsule Achieves First Patient Dosing in Phase 3 – Non‑Inferiority Bridging Study vs. Marketed Utidelone Injection in HER2‑Negative Advanced Breast Cancer

Sanofi and Teva Present 44‑Week RELIEVE UCCD Extension Data – TL1A Antibody Duvakitug Sustains Efficacy Across Ulcerative Colitis and Crohn's Disease Endpoints
CompanyDrug

Sanofi and Teva Present 44‑Week RELIEVE UCCD Extension Data – TL1A Antibody Duvakitug Sustains Efficacy Across Ulcerative Colitis and Crohn’s Disease Endpoints

Sino Biopharmaceutical Completes Phase III Enrollment for TQC2731 – Upstream TSLP Antibody Targets Maintenance Treatment of Chronic Rhinosinusitis With Nasal Polyps
CompanyDrug

Sino Biopharmaceutical Completes Phase III Enrollment for TQC2731 – Upstream TSLP Antibody Targets Maintenance Treatment of Chronic Rhinosinusitis With Nasal Polyps

Takeda's VERDICT Study: ENTYVIO‑Driven Disease Clearance Cuts Ulcerative Colitis Complication Risk by Nearly 70% – First Randomized Evidence for a Treat‑to‑Target Paradigm
CompanyDrug

Takeda’s VERDICT Study: ENTYVIO‑Driven Disease Clearance Cuts Ulcerative Colitis Complication Risk by Nearly 70% – First Randomized Evidence for a Treat‑to‑Target Paradigm

Ascentage Pharma's Lisaftoclax Wins CDE Breakthrough Therapy Designation – Bcl‑2 Inhibitor Plus Acalabrutinib Tapped for First‑Line CLL/SLL
CompanyDrug

Ascentage Pharma’s Lisaftoclax Wins CDE Breakthrough Therapy Designation – Bcl‑2 Inhibitor Plus Acalabrutinib Tapped for First‑Line CLL/SLL

GSK Wins FDA Approval for Hibsago (bepirovirsen) – First‑in‑Class Antisense Oligonucleotide Delivers Functional Cure Potential in Chronic Hepatitis B
CompanyDrug

GSK Wins FDA Approval for Hibsago (bepirovirsen) – First‑in‑Class Antisense Oligonucleotide Delivers Functional Cure Potential in Chronic Hepatitis B

Sihuan Pharmaceutical's PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China
CompanyDrug

Sihuan Pharmaceutical’s PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China

Show More